SHV Energy Implements Global Remote LPG Tank Monitoring With Sigfox Netherlands’ 0G Network and Reduces Carbon Emissions
21.10.2021 17:00:00 EEST | Business Wire | Press release
SHV Energy and Sigfox are rolling out a global LPG tank level monitoring solution. The implementation has started in France, Belgium and Germany and is already generating lower carbon emissions and improved customer satisfaction. Over the next three years, 50,000 units will be rolled out worldwide. Sigfox’s IoT (Internet of Things) asset monitoring capability enables SHV Energy to reduce the cost of tank level monitoring, while increasing efficiency and productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005065/en/
SHV Energy LPG tank (Photo: Sigfox)
SHV Energy, a leading global distributor of off-grid energy such as LPG, LNG, biofuels and renewables, with 30 million customers in 25 countries and 16,700 employees, selected to work with Sigfox, a world’s leading IoT communication service provider and 0G network pioneer.
SHV Energy set-up a Telemetry Centre of Excellence and used Sigfox’ solutions and partner Aton SB S.p.A to deliver a homogeneous, global solution for tank level monitoring that provides sophisticated data analytics, and connected smart devices for daily tank level readings. SHV Energy can now optimize delivery routes and schedules, and has improved sustainability by reducing the firm’s carbon footprint.
Additionally, the Sigfox-based solution is considerably more cost-effective than cellular alternatives. Savings stem from low-cost components, no SIM cards, and modest connectivity costs.
“Data collection is critical to the success of our business. Our efforts to streamline this process have been boosted tremendously through the Sigfox solution. We are now able to gather information at an extremely low-cost point, and this enables the wider scale rollout of a homogeneous tank monitoring system across the globe. Sigfox has exceeded our expectations. Its network and technology partners will help to meet our strategic objectives of harnessing the power of telemetry to the fullest,” explains Simon Gilchrist, Global Programme Lead, SHV Energy.
“The global Sigfox 0G network has delivered once again when it comes to providing connectivity solutions that offer a direct environmental benefit. Across multiple territories, and with the support of our Sigfox Operators, our solution for SHV Energy is helping to lower CO2 emissions as remote tank level monitoring ultimately reduces the number of overall site visits and eliminates unnecessary visits,” adds Ian Terblanche, Senior Vice President of Global Sales at Sigfox.
******
About SHV Energy
SHV Energy is a leading global distributor of off-grid energy such as LPG and LNG and is active in the area of sustainable fuels and renewable energy solutions.
SHV Energy is a wholly owned subsidiary of SHV, a family-owned multinational, and consists of a group of specialised energy companies. Our brands include Calor, Ipragaz, Liquigas, Primagaz and Supergasbras a.o. With these companies, we provide decentralised, low-carbon and clean energy solutions to 30 million business and residential customers off the energy grid.
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Aton
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005065/en/
Contact information
Press Contact
Sigfox
Antoine Mège, Corporate Communications
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
